RLC (n=90) | NLC (n=91) | |
---|---|---|
Women, n (%) | 67 (74.44) | 67 (73.63) |
Age, years, mean (SD) | 57.27 (12.20) | 60.20 (11.26) |
Disease duration, years, mean (SD) (89; 90)* | 10.21 (11.47) | 9.57 (9.84) |
Comorbidities, n (%) | ||
Osteoarthritis | 4 (4.44) | 5 (5.49) |
Osteoporosis | 16 (17.78) | 9 (9.89) |
Hypertension | 19 (21.11) | 20 (21.98) |
Asthma | 7 (7.78) | 6 (6.59) |
Depression | 3 (3.33) | 1 (1.10) |
Hypothyroidism | 6 (6.67) | 1 (1.10) |
Baseline RA regimen, n (%) | ||
Methotrexate | 57 (63.33) | 62 (68.13) |
Sulfasalazine | 16 (17.78) | 9 (9.89) |
Hydroxychloroquine | 4 (4.44) | 3 (3.30) |
Leflunomide | 6 (6.67) | 4 (4.40) |
Prednisolone | 11 (12.22) | 6 (6.59) |
Biological DMARD | 6 (6.67) | 15 (16.48) |
Outcomes, mean (SD) | ||
DAS28 (86; 88)* | 3.89 (1.54) | 3.65 (1.24) |
Pain (0–100 VAS, 0=no pain) (86; 87)* | 39.33 (21.26) | 43.29 (23.77) |
Fatigue (0–100 VAS, 0=no fatigue) (86; 87)* | 49.58 (25.09) | 49.92 (24.50) |
Stiffness (0 –240 Min, 0=no stiffness) (84; 87)* | 50.50 (63.42) | 43.78 (55.50) |
RAQoL (0–30, 0=better quality of life) (76; 78)* | 13.54 (7.05) | 13.33 (8.09) |
HAQ (0–3, 0=no disability) (86; 83)* | 1.25 (0.76) | 1.19 (0.77) |
Anxiety (0–21, 0=no anxiety) (87; 84)* | 7.56 (4.24) | 7.13 (3.83) |
Depression (0–21, 0=no depression) (87; 84)* | 6.20 (3.74) | 5.94 (3.84) |
ASES (11–110, 11=poor self-efficacy) (85; 84)* | 55.53 (17.49) | 59.14 (18.98) |
Satisfaction, median (IQR) | ||
LSQ–General (1–5), 1=dissatisfied) (86; 83)* | 2.7 (2.3, 3.4) | 2.7 (2.3, 3.7) |
LSQ–Information (1–5), 1=dissatisfied) (86; 83)* | 3.2 (3.0, 3.5) | 3.0 (2.9, 3.7) |
LSQ–Empathy (1–5), 1=dissatisfied) (86; 83)* | 3.1 (3.0, 3.6) | 3.0 (2.9, 3.6) |
LSQ–Technical (1–5), 1=dissatisfied) (86; 83)* | 3.2 (3.0, 4.0) | 3.1 (2.9, 4.0) |
LSQ–Attitude (1–5), 1=Dissatisfied) (86; 83)* | 3.2 (3.0, 3.7) | 3.2 (2.8, 3.8) |
LSQ–Access (1–5), 1=dissatisfied) (86; 83)* | 3.1 (3.0, 3.6) | 3.1 (3.0, 3.5) |
ASES, arthritis self-efficacy scale; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; HAQ: health assessment questionnaire disability index; LSQ, Leeds satisfaction questionnaire; NLC, nurse-led clinic; RA, rheumatoid arthritis; RAQoL, rheumatoid arthritis quality of life; RLC, theumatologist-led clinic; VAS, visual analogue scale.
*Number of available data were as per randomised allocation that is, 90 for RLC and 91 for NLC unless otherwise stated in parentheses.